KLOW (Tesofensine) 80mg Research Compound
KLOW contains tesofensine — a triple monoamine reuptake inhibitor (serotonin, dopamine, and norepinephrine) originally developed by NeuroSearch for neurodegenerative disease before attracting significant research interest for CNS-mediated metabolic and appetite regulation. As an oral small molecule rather than an injectable peptide, tesofensine occupies a distinct mechanistic niche in metabolic research, acting centrally through monoaminergic pathways rather than peripheral incretin receptors. This 80mg vial provides research-grade tesofensine at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
A Phase 2 randomized controlled trial published in The Lancet (2008) studied tesofensine in 203 obese participants over 24 weeks. At 0.5mg/day, mean weight loss was 12.8 kg — approximately 11.3% of body weight — versus 1.0 kg in placebo. At 1.0mg/day, mean weight loss reached 14.1 kg. These outcomes, combined with favorable lipid and waist circumference data, established tesofensine as one of the most potent CNS-acting weight-loss compounds in the published literature at the time of the trial.
For a full breakdown of tesofensine’s mechanism, Lancet trial data, dosage reference, and comparison with GLP-1 agonists, see our Tesofensine Research Guide.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 80mg per vial
- Storage: −20°C, protected from light
- Active compound: Tesofensine
- CAS Number: 402856-42-2
Certificate of Analysis
All KLOW vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
